Physician profile
Jesse B Mckey
NPI 1942428867
$12,649.14
in general payments reported to CMS, 2019-2025
28 companies · $1,339 in 2025
The $1,339 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,545 · 2020: $594 · 2021: $1,467 · 2022: $1,717 · 2023: $1,181 · 2024: $4,807 · 2025: $1,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,675 · Food and Beverage: $3,652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,675.00 |
| Food and Beverage | $3,651.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $3,929.13 | 2020-2025 | Cirrus 6000 With Angioplex, Humphrey Field Analyzer (Hfa3), Forum Glaucoma Workplace |
| Alcon Vision LLC | $2,524.50 | 2019-2025 | Lensx, Clareon, Argos |
| Glaukos Corporation | $2,233.33 | 2019-2025 | Idosetr, Ce-Marked Kxla System, Idose |
| Johnson & Johnson Surgical Vision, INC. | $717.10 | 2019-2025 | Tecnis Iol, Tecnis Simplicity |
| Abbvie INC. | $464.00 | 2022-2024 | |
| Microsurgical Technology, INC. | $430.13 | 2024-2025 | |
| Carl Zeiss Meditec USA, INC. | $410.20 | 2021-2024 | |
| Bausch & Lomb Americas INC. | $405.49 | 2022-2025 | Envista Mx60 Iol, Vyzulta |
| Rxsight INC | $249.23 | 2022-2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $242.98 | 2019-2021 | |
| Allergan, INC. | $217.97 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $160.57 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $86.61 | 2019-2021 | |
| Oyster Point Pharma, INC. | $76.27 | 2022-2023 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $69.92 | 2024 | Xdemvy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $58.83 | 2019-2025 | |
| Ocular Therapeutix, INC. | $53.22 | 2021-2023 | Dextenza |
| Amgen INC. | $51.33 | 2024-2025 | Tepezza |
| Ucb, INC. | $48.72 | 2024-2025 | Rystiggo |
| Kala Pharmaceuticals, INC. | $36.25 | 2020-2021 | |
| Harrow Eye, LLC | $31.23 | 2024-2025 | |
| Sight Sciences, INC. | $27.94 | 2025 | Omni Surgical System |
| Mallinckrodt Enterprises LLC | $23.29 | 2019 | |
| Thea Pharma INC. | $22.30 | 2025 | Iyuzeh |
| Dompe US, INC. | $21.89 | 2024 | Oxervate |
| Merz North America, INC. | $20.92 | 2019 | |
| Optovue, INC. | $18.61 | 2019 | |
| Celularity INC. | $17.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Mckey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.